Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2020 - 2021)

Lyell Immunopharma (LYEL) reported Preferred Stock Liabilities of $1.0 billion for Q1 2021, little changed sequentially from $1.0 billion in Q4 2020.

Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Lyell Immunopharma (LYEL) has 2 years of Preferred Stock Liabilities data on file, last reported at $1.0 billion in Q1 2021.

For the quarter ending Q1 2021, Preferred Stock Liabilities changed N/A year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2021 stood at $1.0 billion (changed N/A YoY), and the FY2020 full-year result was $1.0 billion, up 94.73% from the prior year.
Preferred Stock Liabilities steadied at $1.0 billion in Q1 2021, from $1.0 billion in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $1.0 billion in Q2 2020 to a low of $1.0 billion in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Lyell Immunopharma	298.14 Mn	298.14 Mn	-	-

Download Data